2018
To chelate or not to chelate in MDS: That is the question!
Zeidan AM, Griffiths EA. To chelate or not to chelate in MDS: That is the question! Blood Reviews 2018, 32: 368-377. PMID: 29602612, DOI: 10.1016/j.blre.2018.03.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsIron chelation therapyMyelodysplastic syndromeIron overloadMDS patientsChronic transfusion supportAcute myeloid leukemiaBone marrow failureDisease-related alterationsTransfusion supportSurvival impactRandomized trialsInferior outcomesMyeloid leukemiaChelation therapyClinical consequencesMarrow failurePatientsHeterogeneous groupIron metabolismTherapyInherent risksSyndromePhysical manifestationsLeukemiaHemopathies
2017
Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome
Zeidan AM, Pullarkat VA, Komrokji RS. Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome. Critical Reviews In Oncology/Hematology 2017, 117: 57-66. PMID: 28807236, DOI: 10.1016/j.critrevonc.2017.07.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsChelation TherapyHumansIron Chelating AgentsIron OverloadMyelodysplastic SyndromesPrognosisConceptsIron chelation therapyIron overloadMyelodysplastic syndromeFrequent red blood cell transfusionsLower-risk myelodysplastic syndromesRed blood cell transfusionLow-risk MDS patientsHeterogeneous hematopoietic neoplasmsRandomized trial evidenceBlood cell transfusionAcute myeloid leukemiaTissue iron depositionCell transfusionSupportive careMDS patientsTrial evidenceMyeloid leukemiaChelation therapyThalassemia patientsIneffective erythropoiesisBetter survivalPatientsEndocrine toxicityIron depositionHematopoietic neoplasms
2015
Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes
Zeidan AM, Hendrick F, Friedmann E, Baer MR, Gore SD, Sasane M, Paley C, Davidoff AJ. Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes. Journal Of Comparative Effectiveness Research 2015, 4: 327-340. PMID: 26274794, PMCID: PMC5549705, DOI: 10.2217/cer.15.20.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeMortality riskDeferasirox therapyOlder MDS patientsICD-9 codesIron chelation therapyEnd of studyMarginal structural modelsTransfusion thresholdMDS patientsMedicare patientsChelation therapyMedicare claimsMedicare populationPatientsBlood unitsAbstractTextTherapySignificant reductionSyndromeRiskWeeksMortality